Alembic Pharma gets USFDA nod for bipolar disorder treatment drug
In a regulatory filing, Alembic Pharmaceuticals said it has received approval from the US Food and Drug Administration (USFDA) for its abbreviated new drug application (ANDA) for Asenapine Sublingual Tablets in the strengths of 5 mg and 10 mg.
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news
More News: Biotechnology | Bipolar | Food and Drug Administration (FDA) | Mania | New Drug Applications | Pharmaceuticals